Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus HEPATAMINE 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus HEPATAMINE 8.
AMINOSYN II 15% IN PLASTIC CONTAINER vs HEPATAMINE 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%.
Category C
Category C
Amino Acid Solution
Amino Acid Solution